Published in Chest on June 17, 2010
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management | NCT00370214
Clinical features of paediatric pulmonary hypertension: a registry study. Lancet (2012) 2.13
Estrogen rescues preexisting severe pulmonary hypertension in rats. Am J Respir Crit Care Med (2011) 1.91
Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates. Ann Thorac Med (2014) 1.40
Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J (2012) 1.39
New mechanisms of pulmonary arterial hypertension: role of Ca²⁺ signaling. Am J Physiol Heart Circ Physiol (2012) 1.24
The genetic basis of pulmonary arterial hypertension. Hum Genet (2014) 1.14
MicroRNAs in pulmonary arterial remodeling. Cell Mol Life Sci (2013) 0.99
Pulmonary hypertension surveillance: United States, 2001 to 2010. Chest (2014) 0.99
Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. Br J Pharmacol (2014) 0.97
Causes of pulmonary hypertension in the elderly. Chest (2014) 0.97
Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension. Pulm Circ (2012) 0.95
Prevalence and clinical characteristics associated with pulmonary hypertension in African-Americans. PLoS One (2013) 0.94
Pulmonary hypertension in Portugal: first data from a nationwide registry. Biomed Res Int (2013) 0.90
Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover Conference series). Pulm Circ (2014) 0.90
Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey. Mayo Clin Proc (2011) 0.89
Severe pulmonary hypertension: The role of metabolic and endocrine disorders. Pulm Circ (2012) 0.87
The genetics of pulmonary arterial hypertension in the post-BMPR2 era. Pulm Circ (2011) 0.87
Estrogen paradox in pulmonary hypertension: current controversies and future perspectives. Am J Respir Crit Care Med (2012) 0.86
Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension. J Korean Med Sci (2015) 0.85
Trends in pulmonary hypertension mortality and morbidity. Pulm Med (2014) 0.83
Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulm Med (2014) 0.83
NADPH oxidases: key modulators in aging and age-related cardiovascular diseases? Clin Sci (Lond) (2016) 0.82
Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension. J Thorac Dis (2016) 0.82
Recent advances in the management of pulmonary arterial hypertension. F1000Res (2016) 0.80
Capillary pCO2 helps distinguishing idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction. Respir Res (2015) 0.79
Effect of Age on Phenotype and Outcomes in Pulmonary Arterial Hypertension Trials. Chest (2016) 0.78
Early initiation of prostacyclin in portopulmonary hypertension: 10 years of a transplant center's experience. Lung (2013) 0.78
EET-dependent potentiation of pulmonary arterial pressure: sex-different regulation of soluble epoxide hydrolase. Am J Physiol Lung Cell Mol Physiol (2015) 0.78
Sex hormones and vascular protection in pulmonary arterial hypertension. J Cardiovasc Pharmacol (2010) 0.77
Sex differences in the pulmonary circulation: implications for pulmonary hypertension. Am J Physiol Heart Circ Physiol (2014) 0.77
Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis. Medicine (Baltimore) (2016) 0.77
Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest (2013) 0.77
Recent strategies in treatment of pulmonary arterial hypertension, a review. Glob J Health Sci (2015) 0.76
Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension. Pulm Circ (2014) 0.76
Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T (2014) 0.76
High levels of serum lactate dehydrogenase correlate with the severity and mortality of idiopathic pulmonary arterial hypertension. Exp Ther Med (2015) 0.75
Pulmonary Hypertension - New Trends of Diagnostic and Therapy. Med Arch (2016) 0.75
Which prognostic factors should be used in pulmonary arterial hypertension in elderly patients? J Geriatr Cardiol (2017) 0.75
Three-dimensional micro computed tomography analysis of the lung vasculature and differential adipose proteomics in the Sugen/hypoxia rat model of pulmonary arterial hypertension. Pulm Circ (2016) 0.75
Can pulmonary arterial hypertension be diagnosed by an elevated pulmonary capillary wedge pressure outside of the guideline criteria? Chest (2011) 0.75
Clinical and hemodynamic profiles of elderly patients with pulmonary arterial hypertension: a single center, prospective study. J Geriatr Cardiol (2017) 0.75
How to select the appropriate candidate of pulmonary arterial hypertension: specific therapy in elderly patients with pulmonary hypertension. J Geriatr Cardiol (2017) 0.75
Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH. Respir Res (2016) 0.75
Novel approaches to pulmonary arterial hypertension drug discovery. Expert Opin Drug Discov (2016) 0.75
World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology. Cardiol Clin (2016) 0.75
4,4'-Methylenedianiline Alters Serotonergic Transport in a Novel, Sex-Specific Model of Pulmonary Arterial Hypertension in Rats. Toxicol Sci (2015) 0.75
Rehospitalization is driving costs in pulmonary arterial hypertension. Am Health Drug Benefits (2013) 0.75
Severe pulmonary hypertension in aging female apolipoprotein E-deficient mice is rescued by estrogen replacement therapy. Biol Sex Differ (2017) 0.75
Pulmonary hypertension in the elderly: a different disease? Breathe (Sheff) (2016) 0.75
Identifying "super responders" in pulmonary arterial hypertension. Pulm Circ (2017) 0.75
Novel approach to classifying patients with pulmonary arterial hypertension using cluster analysis. Pulm Circ (2017) 0.75
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Hyperbaric oxygen for acute carbon monoxide poisoning. N Engl J Med (2002) 8.37
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76
Withdrawal of nonfutile life support after attempted suicide. Am J Bioeth (2013) 7.26
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 5.96
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med (2010) 5.59
Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation (2006) 4.69
Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation (2010) 4.66
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58
Incidence and predictors of cardiac perforation after permanent pacemaker placement. Heart Rhythm (2005) 4.39
Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest (2009) 4.08
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med (2002) 3.91
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64
Pulmonary arterial hypertension. Circulation (2006) 3.62
The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation (2003) 3.45
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA (2004) 3.39
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med (2008) 3.13
Tadalafil therapy for pulmonary arterial hypertension. Circulation (2009) 2.98
Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol (2005) 2.91
Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med (2009) 2.90
Withholding anticoagulation after a negative result on duplex ultrasonography for suspected symptomatic deep venous thrombosis. Ann Intern Med (2004) 2.85
Unexplained pulmonary hypertension in elderly patients. Chest (2007) 2.85
Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol (2006) 2.83
An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest (2012) 2.82
New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol (2005) 2.81
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation (2013) 2.64
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol (2010) 2.55
Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest (2010) 2.35
Adherence to PIOPED II investigators' recommendations for computed tomography pulmonary angiography. Am J Med (2012) 2.35
Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.31
Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. Chest (2005) 2.31
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat (2006) 2.30
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest (2004) 2.30
Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. Circulation (2013) 2.24
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience. J Heart Lung Transplant (2013) 2.23
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21
Clinical features of paediatric pulmonary hypertension: a registry study. Lancet (2012) 2.13
Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol (2008) 2.03
Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. Ann Am Thorac Soc (2015) 2.02
Ethical issues associated with globalization of placebo-controlled in pulmonary arterial hypertension. J Heart Lung Transplant (2010) 2.02
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 2.00
VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. Chest (2015) 1.99
Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med (2005) 1.91
EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest (2014) 1.88
Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology (2006) 1.87
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med (2006) 1.86
Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med (2007) 1.84
Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2005) 1.82
Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transplant (2013) 1.79
Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol (2006) 1.76
Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med (2005) 1.75
Radiation and chest CT scan examinations: what do we know? Chest (2012) 1.73
Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis (2007) 1.72